Immunotech Biopharm Ltd

SEHK:6978 Stock Report

Market Cap: HK$1.2b

Immunotech Biopharm Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Yu Wang

Chief executive officer

CN¥2.6m

Total compensation

CEO salary percentage100.0%
CEO tenure6yrs
CEO ownershipn/a
Management average tenure5.3yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Will Immunotech Biopharm (HKG:6978) Spend Its Cash Wisely?

Dec 30
Will Immunotech Biopharm (HKG:6978) Spend Its Cash Wisely?

We're Hopeful That Immunotech Biopharm (HKG:6978) Will Use Its Cash Wisely

Apr 29
We're Hopeful That Immunotech Biopharm (HKG:6978) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Yu Wang's remuneration changed compared to Immunotech Biopharm's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥309m

Mar 31 2024n/an/a

-CN¥322m

Dec 31 2023CN¥3mCN¥3m

-CN¥335m

Sep 30 2023n/an/a

-CN¥315m

Jun 30 2023n/an/a

-CN¥296m

Mar 31 2023n/an/a

-CN¥307m

Dec 31 2022CN¥4mCN¥4m

-CN¥318m

Sep 30 2022n/an/a

-CN¥333m

Jun 30 2022n/an/a

-CN¥347m

Mar 31 2022n/an/a

-CN¥351m

Dec 31 2021CN¥38mCN¥3m

-CN¥354m

Compensation vs Market: Yu's total compensation ($USD351.18K) is about average for companies of similar size in the Hong Kong market ($USD352.22K).

Compensation vs Earnings: Yu's compensation has been consistent with company performance over the past year.

CEO

Yu Wang (56 yo)

6yrs

Tenure

CN¥2,563,000

Compensation

Dr. Yu Wang serves as the Chief Executive Officer and Chief Technology Officer at Immunotech Biopharm Ltd. since December 2018 and also serves as its Director. Dr. Wang has experience in medical research....

Leadership Team

NamePositionTenureCompensationOwnership
Zheng Tan
Executive Chairman6.7yrsCN¥2.67m19.08%
HK$ 228.8m
Yu Wang
CEO, CTO & Executive Director6yrsCN¥2.56mno data
Hyun Chul Jung
Founder & Chief Strategy Officerno dataCN¥607.00k8.71%
HK$ 104.4m
Yu Zhang
Chief Scientistno datano datano data
Jian Zhang
Senior Vice Presidentno datano datano data
Shui Bing Leung
Company Secretaryless than a yearno datano data

5.3yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 6978's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zheng Tan
Executive Chairman6.7yrsCN¥2.67m19.08%
HK$ 228.8m
Yu Wang
CEO, CTO & Executive Directorno dataCN¥2.56mno data
Chi Kit Ng
Independent Non-Executive Director4.5yrsCN¥268.00kno data
Donghu Wang
Non-Executive Director1.3yrsno datano data
Ran Tao
Non-Executive Director3.3yrsno datano data
Yingdian Wang
Independent Non-Executive Director4.5yrsCN¥275.00kno data
Sujiu Peng
Independent Non-Executive Director4.5yrsCN¥275.00kno data
Ruihua Wang
Non-Executive Director1.8yrsno datano data
Fan Yang
Non-Executive Director1.8yrsno datano data

3.9yrs

Average Tenure

56yo

Average Age

Experienced Board: 6978's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 07:51
End of Day Share Price 2024/12/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunotech Biopharm Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lok Kwan ChiuCCB International Securities Limited
Yidong ZhangIndustrial Securities (HK) Financial Holdings
Qianlan ZhuSPDB International Holdings Limited